SPOTLIGHT -
Phase III Trial Data Demonstrates Efficacy of Lenacapavir in Preventing HIV in Cisgender Women
Results of the PURPOSE 1 trial indicated that treatment with lenacapavir was superior to Descovy and Truvada.
CVS Caremark Issues Statement of Role of PBMs
The PBM defined its core values and what role it believes PBMS should play in the industry.
Vivacelle Bio Launches Phase III Clinical Trial for VBI-S to Treat Hypovolemic Septic Shock
The trial is expected to include 40 patients across the United States who haven’t responded adequately to standard hypovolemic septic shock treatments and are on vasopressors.
FDA Approves Merz Aesthetics’ Xeomin for Simultaneous Treatment of Upper Facial Lines
The new approval expands Xeomin’s indications to include horizontal forehead lines and lateral canthal lines.
Johnson & Johnson Submits Supplemental New Drug Application to FDA for Spravato as Monotherapy for Adults with Treatment-Resistant Depression
Approval of Spravato would mark the first monotherapy to be available on the market for treatment-resistant depression in the United States.
Antheia Announces $17 Million in Funding for Domestic Pharmaceutical Ingredient Production
The company received the money through a government project agreement.
Is There a Correlation Between Medical Debt and Delayed Mental Health Care in the United States?
JAMA study aims to determine whether financial barriers impact access to mental health services.
South Korean Company Announces Development of Oral GLP-1 Treatment
Dx&Vx identified multiple potential drug candidates using AI-based technology.
Genomics plc Extends Partnership with Vertex Pharmaceuticals
The two companies will continue to collaborate on the use of machine learning in improving precision medicine development.
FDA Approves Voquezna for GERD Treatment
This is the latest approval for Phathom Pharmaceutical’s GI treatment.
FDA Grants Orphan Drug Designation to Mabwell’s Treatment of Small Cell Lung Cancer
Novel drug 7MW3711 binds to tumor cell membrane antigens, being internalized and transported to the lysosome, releasing a cytotoxic drug, and inducing tumor cell apoptosis.
CT-996 Demonstrates Significant Weight Loss in Patients with Obesity and Type 2 Diabetes
Treatment with CT-996 led to a significant placebo-adjusted mean weight loss of 6.1% within four weeks in participants with obesity but without type 2 diabetes.
Texas A&M Health Teams With BurstIQ to Improve Genomic Research Data Governance
The tech company’s data platform will be implemented into the genomic research department’s workflow.
Member Defense Network Launches to Prevent Unauthorized Switching in ACA Marketplace
The network includes organizations that represent over 45,000 agents and brokers.
FDA Clears Positrigo’s NeuroLF Brain PET System for the Diagnosis of Multiple Brain Disorders
Clearance of the NeuroLF Brain PET system marks Positrigo’s first device of its kind to be approved in the United States.
FDA Grants Fast Track Designation to Abdera Therapeutics’ Treatment for Extensive-Stage Small Cell Lung Cancer
The novel therapy, ABD-147, uses advanced antibody engineering to deliver Actinium-225 to solid tumors expressing DLL3, a protein found on neuroendocrine tumors.
SOTIO Biotech, Biocytogen Ink Research and License Agreement to Develop Next-Generation Antibody-Drug Conjugates
The agreement enables SOTIO to license multiple fully human bispecific antibodies from Biocytogen's RenLite platform.
Anthem Blue Cross and Allied Pacific IPA Announce Partnership with Astrana Health Inc.
The two companies will use Astrana’s technology offerings to improve access.
FDA Grants Fast Track Designation to Sumitomo Pharma’s Novel Treatment for Patients with Relapsed or Refractory Acute Myeloid Leukemia
DSP-5336 targets the menin and mixed-lineage leukemia protein interaction, crucial in various biological processes, including cell growth and genomic stability.
FDA Clears Artelo Biosciences’ Investigational New Drug Application for Chemotherapy-Induced Peripheral Neuropathy Treatment
Clearance of the New Drug Application for ART25.12 allows Artelo to begin a Phase I study for the drug in chemotherapy-induced peripheral neuropathy.
The Future of Periodontal Treatment
Advancements in periodontal disease could make way for expansions in the dental space and other medical fields.
Cohort Study Compares Weight Loss Effects of Tirzepatide vs. Semaglutide
JAMA study aims to discover how weight loss differs between patients receiving tirzepatide compared with semaglutide among a clinical population of overweight of obese adults.
Amylyx Pharmaceuticals Acquires Phase III-Ready GLP-1 Receptor Agonist Avexitide for Hyperinsulinemic Hypoglycemia from Eiger BioPharmaceuticals
Avexitide has received Breakthrough Therapy Designation by the FDA for post-bariatric hypoglycemia, congenital hyperinsulinism, and more.
AI-Controlled Virtual Assistant Announced for Digital Health Network for Self-Funded Healthcare Plans
Empara’s virtual assistant is the latest attempt to use AI to simplify the user experience in the healthcare industry.
FDA Issues Complete Response Letter to Novo Nordisk for Icodec, a Once-Weekly Basal Insulin for the Treatment of Diabetes Mellitus
According to the Complete Response Letter, the FDA has requested additional information on the manufacturing process and the type 1 diabetes indication for insulin icodec before completing its review.
Johnson & Johnson Inks Deal to Acquire Yellow Jersey Therapeutics in $1.25 Billion All-Cash Deal
Acquisition of Yellow Jersey Therapeutics includes access to NM26, a potential treatment for atopic dermatitis.
What Happens to Out-of-Pocket Costs When Patients with Type 2 Diabetes Reach the Medicare Age?
JAMA study evaluates changes to out-of-pocket costs and utilization of type 2 diabetes medications once patients reach the age of 65 years.
FDA Approves Arcutis Biotherapeutics’ Zoryve to Treat Patients with Mild to Moderate Atopic Dermatitis
Zoryve is a steroid-free, once-daily treatment shown to offer rapid disease clearance and significant itch reduction for patients with mild to moderate atopic dermatitis.
What is the Secret Sauce to Convert Academic Ideas to Valued Offerings That Prospective Buyers Crave?
A Harvard Business School Healthcare Alumni Association Q&A with Penn Center for Innovation’s Michael D. Moisel, MS, MBA.
Revelation Pharma Acquires Pharmacies on Both Coasts, Extending Its Reach
The compounding pharmacy acquired Taylors Pharmacy and Key Compounding Pharmacy.